AML patients with CD34+ leukemia cells show reduced RIPK3 expression while the expression of RIPK1 is not affected leading to suppressed apoptosis, necroptosis, and NF-ĸB pathway [86]. This evidence concerns the gene RIPK1 and acute myeloid leukemia.